CN Patent

CN107847437B — 用于治疗疼痛的塞来昔布口服组合物

Assigned to Dr Reddys Laboratories Ltd · Expires 2024-03-26 · 2y expired

What this patent protects

本发明涉及塞来昔布或其药学上可接受的盐的稳定的口服液体药物组合物。当在pH 2.0的禁食状态模拟胃液(FaSSGF)中在37℃±0.5℃的温度下以50rpm的速度搅拌至少60分钟时，存在于如本文所述的组合物中的塞来昔布不显示任何沉淀。本发明还涉及所述塞来昔布的组合物的制备方法和使用方法。

USPTO Abstract

本发明涉及塞来昔布或其药学上可接受的盐的稳定的口服液体药物组合物。当在pH 2.0的禁食状态模拟胃液(FaSSGF)中在37℃±0.5℃的温度下以50rpm的速度搅拌至少60分钟时，存在于如本文所述的组合物中的塞来昔布不显示任何沉淀。本发明还涉及所述塞来昔布的组合物的制备方法和使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN107847437B
Jurisdiction
CN
Classification
—
Expires
2024-03-26
Drug substance claim
No
Drug product claim
No
Assignee
Dr Reddys Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.